surmount-4 tirzepatide withdrawal weight regain after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Weight regain and cardiometabolic effects

Sources: Cleveland Clinic and NCBI Bookshelf Who Should Take GLP-1 for Weight Loss

Yung-Chieh Huang, M.D., del Hospital General de Veteranos de Taichung en Taiwn, y sus colegas investigaron la asociacin entre el uso de AR GLP-1 y el riesgo de exacerbaciones agudas del asma en una cohorte clnica de 1.070 adolescentes con propensin, de entre 12 y 18 aos, con sobrepeso u obesidad

Tolerability Issues : The adverse events with the GLP-1-based therapies are primarily gastrointestinal and include nausea, vomiting, constipation, or diarrhea [82], leading to meaningful discontinuation rates that limit real-world effectiveness

Wellness/Longevity Weight-related health conditions Obesity is a silent killer